A retrospective analysis of laparoendoscopic single-site myomectomy in giant uterine myoma

Abstract

Abstract Objectives To investigate the safety and feasibility of laparoendoscopic single-site surgery (LESS) for the treatment of giant uterine myoma (diameter ≥ 8.0cm). Methods A retrospective analysis was made on 60 cases of uterine myoma (diameter ≥ 8.0 cm) who underwent laparoscopic myomectomy in Changzhou Second People's Hospital of Nanjing Medical University between April 2020 and April 2022. The patients were divided into a single-site laparoscopic group (LESS group) and a traditional multi-port laparoscopic surgery (MPLS group), with 20 patients in the study group (LESS group) and 40 patients in the control group (MPLS group). Observation and comparison were made between the two groups on demographic, perioperative, and follow-up data. Results All 60 surgeries were successfully completed without conversion. There was no statistically significant difference in estimated blood loss, and the first exhaust time after surgery between the two groups (P > 0.05); the operative time was longer in the LESS group than in the control group (P < 0.05); the length of hospital stay was shorter in the LESS group than in the control group (P < 0.05); The 24-hour visual analogue score (VAS) and body image score (BIS) were lower in the LESS group than in the control group (P < 0.05); the cosmetic score (CS) of the LESS was higher than that of the control group (P < 0.05). Conclusions Laparoendoscopic single-site myomectomy may be safe, feasible, and effective for the treatment of giant myoma (diameter ≥ 8.0cm). Compared with conventional multi-port laparoscopy, Laparoendoscopic single-site takes relatively longer to perform, but the hospital stay is relatively shorter, the postoperative pain is less, and the advantages of the aesthetic incision are outstanding, which meet the aesthetic needs of women and deserve a further clinical promotion.